NASDAQ$CYPH
Cypherpunk Technologies Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2021.
Leap Therapeutics reported a net loss of $11.1 million for the third quarter of 2021, with license revenues of $0.4 million. Research and development expenses increased to $10.1 million, and cash and cash equivalents totaled $124.8 million at the end of the quarter.
- Presented positive new data at ESMO of DKN-01 in combination with BeiGene’s tislelizumab and chemotherapy.
- Data demonstrated compelling overall response rates in patients with first-line gastric or gastroesophageal junction (G/GEJ) cancer.
- Observed particularly strong responses in patients whose tumors expressed high levels of DKK1 or low PD-L1.
- Looking forward to presenting additional data from the DisTinGuish study early next year and aggressively advancing DKN-01 into the next stages of development in G/GEJ and other cancers.
Headline financials
Revenue & EPS history
Leap Therapeutics · Revenue · Quarterly
$375K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+11.8%
Avg return
Earnings day
+13.6%
Avg return
5 days after
+11.4%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+389.9%
Q3 2025
Best reaction
-44.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +389.9% | +454.8% | +228.8% | |
| Q2 2025 | -28.3% | -15.6% | -11.8% | |
| Q1 2025 | -2.5% | -12.4% | -0.5% | |
| Q4 2024 | +16.9% | -21.4% | +3.1% | |
| Q3 2024 | -11.1% | -14.5% | -9.2% | |
| Q1 2024 | -1.1% | -5.4% | -22.1% | |
| Q4 2023 | -0.5% | +14.0% | +35.7% | |
| Q3 2023 | +13.0% | +32.6% | +128.3% | |
| Q2 2023 | +7.6% | -8.9% | -28.4% | |
| Q1 2023 | +17.1% | +44.4% | +44.4% | |
| Q4 2022 | -12.1% | -0.9% | +11.5% | |
| Q3 2022 | +12.0% | -3.2% | -17.7% | |
| Q2 2022 | +10.0% | -0.8% | +30.0% | |
| Q1 2022 | +34.6% | +25.4% | +10.0% | |
| Q4 2021 | -8.6% | +2.3% | +0.0% | |
| Q3 2021 | +0.4% | +0.8% | +2.9% | |
| Q2 2021 | +0.6% | +3.6% | -12.0% | |
| Q1 2021 | +9.5% | +8.8% | +21.6% | |
| Q4 2020 | +7.9% | +6.1% | -21.1% | |
| Q3 2020 | +0.6% | -3.1% | +21.4% | |
| Q2 2020 | -3.1% | +0.3% | -5.6% | |
| Q1 2020 | +0.0% | +0.4% | +3.1% | |
| Q4 2019 | -4.1% | -14.2% | +20.3% | |
| Q3 2019 | -44.0% | -33.7% | -29.7% | |
| Q2 2019 | -8.9% | -10.2% | +2.5% | |
| Q1 2019 | -1.6% | -6.5% | -0.6% | |
| Q4 2018 | +10.7% | +4.3% | -9.1% | |
| Q3 2018 | -8.8% | -17.1% | -26.8% | |
| Q2 2018 | +2.1% | +6.1% | +8.7% | |
| Q4 2017 | -1.4% | +1.2% | +30.8% | |
| Q3 2017 | -2.1% | +16.9% | +9.2% | |
| Q2 2017 | -5.6% | +2.0% | -6.2% | |
| Q1 2017 | +8.6% | +10.4% | -8.9% | |
| Q4 2016 | +4.0% | -4.7% | -16.2% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro